American Renal Associates Holdings, Inc. (NYSE:ARA) Files An 8-K Results of Operations and Financial ConditionItem 2.02
Results of Operations and Financial Condition.
American Renal Associates Holdings, Inc. (NYSE:ARA) Files An 8-K Results of Operations and Financial Condition
On August8, 2017, American Renal Associates Holdings, Inc. issued a press release announcing its financial and operating results for the second quarter ended June30, 2017.A copy of the press release is furnished with this report as Exhibit 99.1 and is incorporated by reference into this item.
As provided in General Instruction B.2 of Form 8-K, the information and exhibit contained in this report shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
|
Item 2.02. |
Financial Statements and Exhibits. |
(d) Exhibits.
|
Exhibit Number |
Description |
|
99.1 |
Press release, dated August 8, 2017, announcing the registrant’s financial and operating results for the second quarter ended June 30, 2017. |
American Renal Associates Holdings, Inc. ExhibitEX-99.1 2 a6302017-991earningsrelease.htm EXHIBIT 99.1 Document AMERICAN RENAL ASSOCIATES HOLDINGS,…To view the full exhibit click here
About American Renal Associates Holdings, Inc. (NYSE:ARA)
American Renal Associates Holdings, Inc. is a dialysis services provider in the United States. The Company focuses on joint venture partnerships with physicians. The Company’s segment is the ownership and operation of dialysis clinics. It provides patient care and clinical outcomes to patients suffering from the advanced stage of chronic kidney disease, known as end stage renal disease (ESRD). It operates clinics through a joint venture (JV) model, in which it partners with local nephrologists to develop, own and operate dialysis clinics. Each of its clinics is maintained as a separate joint venture in which it has the controlling interest, and its nephrologist partners and other joint venture partners have a non-controlling interest. The Company opens over 20 de novo clinics each year. The Company has owned and operated over 190 dialysis clinics in partnership with approximately 350 nephrologist partners treating over 13,000 patients in over 20 states and the District of Columbia.